Literature DB >> 6619930

Presence of immunosuppressive factors in brain-tumor cyst fluid.

K Kikuchi, E A Neuwelt.   

Abstract

The present investigation was conducted to examine the effects upon normal lymphocyte activation of the addition of brain-tumor cyst fluid or cerebrospinal fluid (CSF) to an in vitro culture system. It was believed that factors present in these fluids may play a role in local and systemic immunosuppression in brain-tumor patients. The authors evaluated the effect of the cyst fluid, CSF, and serum from eight patients with brain tumors (one astrocytoma, five glioblastoma multiforme, one medulloblastoma, and one microglioma) on mitogen-stimulated lymphocyte function as measured by 3H-thymidine incorporation, cell size distribution, and cellular proliferation. Lymphocytes from normal volunteers were incubated for 90 hours in culture medium with 10% pooled human serum, mitogens (phytohemagglutinin, concanavalin A, and pokeweed mitogen), and a range of volumes of cyst fluid or CSF from the tumor patients. Significant suppression of mitogen-induced activation of the lymphocytes was demonstrated in the presence of cyst fluid from five out of six patients, but the mitogen response was only minimally affected by the addition of the CSF from these patients to the culture medium. The suppression of lymphocyte activation by cyst fluid was directly proportional in several cases to the concentration of the cyst fluid. The total protein, albumin, and immunoglobulin (Ig) concentrations in the cyst fluids were observed to roughly correspond to the serum levels and were much higher than in CSF. These studies suggest that brain-tumor cells locally produce lymphocyte-suppressive factors which may then be released into blood. Preliminary characterization of the suppressive factor(s) responsible for the inhibition of lymphocyte function indicates that they are non-dialyzable and do not appear to be an IgG.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6619930     DOI: 10.3171/jns.1983.59.5.0790

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

Authors:  B Frankel; S L Longo; G W Canute
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Immunosuppressive mechanisms in glioblastoma.

Authors:  Edjah K Nduom; Michael Weller; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 3.  The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Authors:  Amy B Heimberger; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

4.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Immunosuppressive acidic protein in patients with brain tumours: a preliminary report.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

6.  Immunopathological features of human pulmonary tumors following low-dose interleukin-2.

Authors:  S G Swisher; T M Anderson; D R Wen; M A Stene; A J Cochran; S H Golub; E C Holmes
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  A correlation between serum immunosuppressive acidic protein and altered immunocompetence in patients with brain tumours.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

8.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine.

Authors:  Andrew T Parsa; John I Miller; Arnold E Eggers; Alfred T Ogden; Richard C Anderson; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

10.  Cyst fluid of glioma does not inhibit the killing action of lymphokine-activated killer (LAK) cells in vitro.

Authors:  J Jääskeläinen; P Kalliomäki; A Paetau; E Saksela; T Timonen
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.